Skip to main content Accessibility help
×
×
Home

Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial

  • Nikolai Albert (a1), Lasse Randers (a1), Kelly Allott (a2) (a3), Heidi Dorthe Jensen (a1), Marianne Melau (a1), Carsten Hjorthøj (a1) and Merete Nordentoft (a1) (a4)...

Abstract

Background

The effect of antipsychotics medication on cognitive functioning in patients diagnosed with schizophrenia is poorly understood. Some studies of second generation antipsychotics indicated that they improved cognitive functioning while other studies have found that they decrease the level of cognitive functioning.

Method

We included patients with schizophrenia who were in treatment with antipsychotics 1.5 years (baseline) after initiation of treatment and followed them up 3.5 years later (n = 189). At follow-up 60 (32%) had discontinued their antipsychotic treatment and 129 (68%) were still taking antipsychotics. Using the Brief Assessment of Cognition in Schizophrenia (BACS) we assessed cognition at baseline and follow-up.

Results

The patients who discontinued their medication had a higher level of cognitive functioning in all domains at baseline, as well as Global cognitive function [mean z-score −1.50 (s.d. 1.24) v. −2.27 (s.d. 1.30), p = 0.00015]. After controlling for relevant confounders those who discontinued antipsychotic medication improved significantly more than those who remained on antipsychotic medication during the course of the follow-up on the Token Motor task [estimated mean change difference −0.46 (95% CI −0.89 to −0.04)], the Speed of Processing Domain [estimated mean change difference −0.38 (95% CI −0.68 to −0.08)] and global cognition [estimated mean change difference −0.36 (95% CI −0.66 to −0.07)].

Conclusion

Due to the naturalistic design, we cannot conclude on the direction of the relationship between antipsychotics and cognition. There is no evidence that discontinuation of medication had a negative effect on cognitive functioning. Rather, we found that that discontinuation of medication was associated with better cognitive functioning.

Copyright

Corresponding author

Author for correspondence: Nikolai Albert, E-mail: nikolai.albert@regionh.dk

References

Hide All
Albert, N, Melau, M, Jensen, H, Emborg, C, Jepsen, J, Fagerlund, B, Gluud, C, Mors, O, Hjorthøj, C and Nordentoft, M (2017) Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUS II). BMJ 356. Available at https://doi.org/10.1136/bmj.i6681.
Allott, K, Fraguas, D, Bartholomeusz, C, Diaz-Caneja, C, Wannan, C, Parrish, E, Amminger, G, Pantelis, C, Arango, C, McGorry, P and Rapado-Castro, M (2017) Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: a systematic review and meta-analysis. Psychological Medicine 48, 15921607.
Andreasen, NC (1984) Scale for Assessment of Negative Symptoms/Scale for Assessment of Positive Symptoms. Iowa City: University of Iowa Press.
Bozikas, VPP and Andreou, C (2011) Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Australian & New Zealand Journal of Psychiatry 45, 93108.
Désaméricq, G, Schurhoff, F, Meary, A, Szöke, A, Macquin-Mavier, I, Bachoud-Lévi, AC and Maison, P (2014) Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. European Journal of Clinical Pharmacology 70, 127134.
Elie, D, Poirier, M, Chianetta, J, Durand, M, Gregoire, C and Grignon, S (2010) Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychopharmacology 24, 10371044.
Faber, G, Smid, HGOM, Van Gool, AR, Wiersma, D, Van, RJ and Bosch, D (2011) The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. European Psychiatry 27, 275280.
Fett, AKJ, Viechtbauer, W, Dominguez, M, de, G, Penn, DL, van Os, J and Krabbendam, L (2011) The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neuroscience and Biobehavioral Reviews 35, 573588.
Fink-Jensen, A, Rasmussen, I, Viuff, A, Larsen, J, Scmidt, M, Peacock, L, Stenstrøm, A, Glintborg, D, Brøsen, K, Gudik-Sørensen, M, Glenthøj, B, Pagsberg, A and Baandrup, L (2016) Behandlingsvejledning for medicinsk behandling af psykotiske tilstande hos voksne. RADS – Raadet for Anvendelse Af Dyr Sygehusmedicin.
Gardner, DM, Murphy, AL, O'Donnell, H, Centorrino, F and Baldessarini, RJ (2010) International consensus study of antipsychotic dosing. American Journal of Psychiatry 167, 686693.
Glenthøj, L, Fagerlund, B, Randers, L, Hjorthøj, C, Wenneberg, C, Krakauer, K, Vosgerau, A, Gluud, C, Medalia, A, Roberts, D and Nordentoft, M (2015) The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial. Trials 16, 110.
Harrow, M, Jobe, TH and Faull, RN (2012) Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychological Medicine 42, 21452155.
Harvey, PD and Keefe, RSE (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry 158, 176184.
Husa, A, Rannikko, I, Moilanen, J, Haapea, M, Murray, G, Barnett, J, Jones, P, Isohanni, M, Koponen, H, Miettunen, J and Jääskeläinen, E (2014) Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia – an observational 9-year follow-up study. Schizophrenia Research 158, 134141.
Keefe, RSE, Goldberg, TE, Harvey, PD, Gold, JM, Poe, MP and Coughenour, L (2004 a) The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research 68, 283297.
Keefe, R, Seidman, LJ, Christensen, BK, Hamer, RM, Sharma, T, Sitskoorn, M, Lewine, R, Yurgelun-Todd, D, Gur, R, Tohen, M, Tollefson, G, Sanger, T, Lieberman, J and HGDH Research Group (2004 b) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. The American Journal of Psychiatry 161, 985.
Knowles, EEM, David, AS and Reichenberg, A (2010) Processing speed deficits in schizophrenia: reexamining the evidence. The American Journal of Psychiatry 167, 828835.
Leucht, S, Arbter, D, Engel, RR, Kissling, W and Davis, JM (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry 14, 429447.
Lingjaerde, O, Ahlfors, U, Bech, P, Dencker, S and Elgen, K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum 334, 1100.
Lynge, E, Sandegaard, JL and Rebolj, M (2011) The Danish National Patient Register. Scandinavian Journal of Public Health 39 (Suppl. 7), 3033.
Marshall, M, Lewis, S, Lockwood, A, Drake, R, Jones, P and Croudace, T (2005) Association between duration of untreated psychosis and outcome in cohorts of first-episode patients. Archives of General Psychiatry 62, 975983.
Melau, M, Jeppesen, P, Thorup, A, Bertelsen, M, Petersen, L, Gluud, C, Krarup, G and Nordentoft, M (2011) The effect of five years versus two years of specialised assertive intervention for first episode psychosis – OPUS II: study protocol for a randomized controlled trial. Trials 12, 72.
Mesholam-Gately, RI, Giuliano, AJ, Goff, KP, Faraone, SV and Seidman, LJ (2009) Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 23, 315336.
Moilanen, J, Haapea, M, Miettunen, J, Jääskeläinen, E, Veijola, J, Isohanni, M and Koponen, H (2013) Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication – a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. European Psychiatry: The Journal of the Association of European Psychiatrists 28, 5358.
Morosini, PL, Magliano, L, Brambilla, L, Ugolini, S and Pioli, R (2000) Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica 101, 323329.
Murray, R, Quattrone, D, Natesan, S, Van Os, J, Nordentoft, M, Howes, O, Di Forti, M and Taylor, D (2016) Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics. British Journal of Psychiatry 209, 361365.
Nuechterlein, KH, Barch, DM, Gold, JM, Goldberg, TE, Green, MF and Heaton, RK (2004) Identification of separable cognitive factors in schizophrenia. Schizophrenia Research 72, 2939.
Perkins, DO, Gu, H, Boteva, K and Lieberman, JA (2005) Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. The American Journal of Psychiatry 162, 17851804.
Potkin, SG, Fleming, K, Jin, Y and Gulasekaram, B (2001) Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. Journal of Clinical Psychopharmacology 21, 479483.
Schaefer, J, Giangrande, E, Weinberger, DR and Dickinson, D (2013) The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophrenia Research 150, 4250.
Statistics Denmark (n.d.) “The DREAM database, Statistics Denmark”. Available at http://www.dst.dk/da/TilSalg/Forskningsservice/Data/Andre_Styrelser.aspx#.
Szoke, A, Trandafir, A, Dupont, M, Meary, A, Schurhoff, F and Leboyer, M (2008) Longitudinal studies of cognition in schizophrenia: meta-analysis. British Journal of Psychiatry 192, 248257.
Takeuchi, H, Suzuki, T, Remington, G, Bies, R, Abe, T, Graff-Guerrero, A, Watanabe, K, Mimura, M and Uchida, H (2013) Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia Bulletin 39, 993998.
Weickert, TW, Goldberg, TE, Marenco, S, Bigelow, LB, Egan, MF and Weinberger, DR (2003) Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 28, 14911500.
Wils, R, Gotfredsen, D, Hjorthøj, C, Austin, S, Albert, N, Secher, R, Thorup, A, Mors, O and Nordentoft, M (2016) Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophrenia Research 182, 4248.
Wing, JK, Sartorius, N and Üstun, TB (1998) WHO Diagnosis and Clinical Measurement in Psychiatry. A Reference Manual for SCAN. Cambridge: Cambridge University Press.
World Health Organization (1993) The ICD-10 Classification of Mental and Behavioural Disorders, Diagnostic Criteria for Research, 1st Edn. Geneva: World Health Organization.
Wunderink, L, Nieboer, RM, Wiersma, D, Sytema, S and Nienhuis, FJ (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70, 913920.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Type Description Title
WORD
Supplementary materials

Albert et al. supplementary material
Albert et al. supplementary material 1

 Word (16 KB)
16 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed